MCID: GRD007
MIFTS: 56

Grade Iii Astrocytoma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Grade Iii Astrocytoma

MalaCards integrated aliases for Grade Iii Astrocytoma:

Name: Grade Iii Astrocytoma 12 49 14
Anaplastic Astrocytoma 12 49 55 51 69
Grade Iii Astrocytic Tumor 12

Characteristics:

Orphanet epidemiological data:

55
anaplastic astrocytoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3078
MeSH 41 D001254
NCIt 46 C9477
SNOMED-CT 64 55353007
Orphanet 55 ORPHA251589
UMLS via Orphanet 70 C0334579
ICD10 via Orphanet 33 C71.9
UMLS 69 C0334579

Summaries for Grade Iii Astrocytoma

NIH Rare Diseases : 49 Anaplastic astrocytoma is a rare, cancerous (malignant) type of brain tumor that arises from star-shaped brain cells called astrocytes. These cells surround and protect nerve cells in the brain and spinal cord. An anaplastic astrocytoma usually develops slowly over time, but may develop rapidly. Signs and symptoms vary depending on the location and size of the tumor and may include headaches, drowsiness, vomiting, and changes in personality or mental status. Some affected people have seizures, vision problems, weakness of the limbs, and/or coordination problems. Anaplastic astroctyomas usually occur sporadically but can be associated with a few rare, genetic disorders. Treatment may include surgery, radiation, and/or chemotherapy. Last updated: 11/3/2014

MalaCards based summary : Grade Iii Astrocytoma, also known as anaplastic astrocytoma, is related to glioblastoma and astrocytoma, and has symptoms including sensory manifestations, motor manifestations and seizures. An important gene associated with Grade Iii Astrocytoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Temodar and Carmustine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are Increased cell death HMECs cells and homeostasis/metabolism

Disease Ontology : 12 An astrocytoma that is characterized by cells with regular, round to oval nuclei.

Related Diseases for Grade Iii Astrocytoma

Diseases related to Grade Iii Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
# Related Disease Score Top Affiliating Genes
1 glioblastoma 26.8 CDK4 CDKN2A DMBT1 EGFR IDH2 MDM2
2 astrocytoma 26.2 CDK4 CDKN2A CDKN2B DMBT1 EGFR GFAP
3 intracranial chondrosarcoma 10.6 IDH2 TP53
4 brain ependymoma 10.5 EGFR TP53
5 frontal convexity meningioma 10.5 GFAP TP53
6 gliofibroma 10.5 GFAP TP53
7 glioma susceptibility 1 10.5 IDH2 TP53
8 brain stem astrocytic neoplasm 10.5 CDKN2A TP53
9 cerebral convexity meningioma 10.5 GFAP TP53
10 squamous cell carcinoma of the oropharynx 10.5 CDKN2A TP53
11 cellular ependymoma 10.5 GFAP TP53
12 cowden syndrome 1 10.5 EGFR PTEN
13 actinic cheilitis 10.5 MDM2 TP53
14 spitz nevus 10.5 CDKN2A TP53
15 female reproductive endometrioid cancer 10.5 PTEN TP53
16 bizarre leiomyoma 10.4 CDKN2A PCNA
17 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
18 malignant peritoneal mesothelioma 10.4 CDKN2A EGFR
19 tumor suppressor gene on chromosome 11 10.4 EGFR PTEN
20 protoplasmic astrocytoma 10.4 GFAP IDH2 TP53
21 gangliocytoma 10.4 GFAP PTEN
22 central nervous system primitive neuroectodermal neoplasm 10.4 GFAP TP53
23 oral leukoplakia 10.4 CDKN2A PCNA TP53
24 oligoastrocytoma 10.4 GFAP IDH2 MGMT
25 pleomorphic xanthoastrocytoma 10.4 GFAP MGMT TP53
26 suppressor of tumorigenicity 3 10.4 CDKN2A PCNA TP53
27 spinal cord astrocytoma 10.4 GFAP MGMT TP53
28 inverted papilloma 10.4 CDKN2A PCNA TP53
29 bartholin's gland benign neoplasm 10.4 CDKN2A TP53
30 gastric adenosquamous carcinoma 10.4 CDKN2A EGFR
31 intrahepatic cholangiocarcinoma 10.3 EGFR IDH2 TP53
32 gemistocytic astrocytoma 10.3 GFAP IDH2 PTEN
33 oropharynx cancer 10.3 CDKN2A EGFR TP53
34 basaloid squamous cell carcinoma 10.3 CDKN2A EGFR TP53
35 cerebral neuroblastoma 10.3 GFAP TP53
36 vulva cancer 10.3 CDKN2A EGFR TP53
37 cornea cancer 10.3 CDK4 GFAP
38 pre-malignant neoplasm 10.3 CDKN2A EGFR TP53
39 central nervous system lymphoma 10.3 CDKN2A MGMT TP53
40 mucinous adenocarcinoma 10.3 CDKN2A EGFR TP53
41 bladder squamous cell carcinoma 10.3 CDKN2A PTEN TP53
42 penile cancer 10.3 CDKN2A EGFR TP53
43 sclerosing liposarcoma 10.3 MDM2 TP53
44 in situ carcinoma 10.3 CDKN2A EGFR TP53
45 spinal cancer 10.3 GFAP TP53
46 pharynx cancer 10.3 CDKN2A EGFR TP53
47 mucinous stomach adenocarcinoma 10.3 PTEN VEGFA
48 ependymoma 10.3 EGFR GFAP MGMT
49 lip cancer 10.3 MDM2 TP53
50 necrotizing sialometaplasia 10.3 CDKN2A GFAP TP53

Graphical network of the top 20 diseases related to Grade Iii Astrocytoma:



Diseases related to Grade Iii Astrocytoma

Symptoms & Phenotypes for Grade Iii Astrocytoma

UMLS symptoms related to Grade Iii Astrocytoma:


sensory manifestations, motor manifestations, seizures, headache

GenomeRNAi Phenotypes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.02 EGFR MDM2 PCNA PTEN TP53

MGI Mouse Phenotypes related to Grade Iii Astrocytoma:

43 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 GFAP EGFR MDM2 DMBT1 CDKN2A CDK4
2 immune system MP:0005387 10.37 EGFR MDM2 GFAP CDK4 CDKN2B CDKN2A
3 cardiovascular system MP:0005385 10.36 GFAP IDH2 EGFR MDM2 CDKN2A CDK4
4 cellular MP:0005384 10.36 DMBT1 GFAP EGFR CDKN2A CDK4 CDKN2B
5 mortality/aging MP:0010768 10.36 GFAP EGFR MDM2 DMBT1 CDK4 CDKN2B
6 endocrine/exocrine gland MP:0005379 10.33 EGFR MDM2 CDK4 CDKN2B CDKN2A PCNA
7 growth/size/body region MP:0005378 10.32 GFAP EGFR CDKN2A CDK4 MMP2 PDGFRA
8 hematopoietic system MP:0005397 10.32 EGFR MDM2 CDKN2A CDK4 CDKN2B MMP2
9 digestive/alimentary MP:0005381 10.3 EGFR MDM2 GFAP DMBT1 CDK4 CDKN2A
10 neoplasm MP:0002006 10.29 EGFR IDH2 MDM2 CDK4 CDKN2B CDKN2A
11 embryo MP:0005380 10.25 EGFR MDM2 DMBT1 CDKN2A CDK4 PDGFRA
12 integument MP:0010771 10.2 EGFR CDKN2A CDK4 CDKN2B PDGFRA MDM2
13 muscle MP:0005369 10.19 GFAP EGFR MDM2 CDK4 CDKN2A PDGFRA
14 nervous system MP:0003631 10.16 GFAP EGFR CDKN2A CDK4 MMP2 PDGFRA
15 craniofacial MP:0005382 10.09 EGFR MMP2 MDM2 TP53 PDGFRA VEGFA
16 no phenotypic analysis MP:0003012 10.09 EGFR MDM2 CDKN2A CDKN2B PCNA MGMT
17 liver/biliary system MP:0005370 10.07 EGFR CDKN2A CDK4 MDM2 PTEN TP53
18 normal MP:0002873 10.06 GFAP EGFR CDK4 MMP2 PDGFRA MDM2
19 limbs/digits/tail MP:0005371 10.01 EGFR MDM2 TP53 PTEN PDGFRA VEGFA
20 renal/urinary system MP:0005367 9.97 EGFR MDM2 DMBT1 CDK4 CDKN2B PDGFRA
21 reproductive system MP:0005389 9.96 EGFR MDM2 CDKN2A CDK4 CDKN2B PCNA
22 pigmentation MP:0001186 9.91 EGFR MDM2 CDKN2A CDK4 PDGFRA TP53
23 respiratory system MP:0005388 9.76 EGFR CDKN2A MMP2 PDGFRA MGMT TP53
24 skeleton MP:0005390 9.56 EGFR CDKN2A MMP2 MDM2 PTEN PDGFRA
25 vision/eye MP:0005391 9.23 GFAP EGFR CDKN2A CDK4 MMP2 TP53

Drugs & Therapeutics for Grade Iii Astrocytoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Temodar 17 45 TEMOZOLOMIDE Schering-Plough August 1999

Drugs for Grade Iii Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 365)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
2
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
3
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
4
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
5
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
6
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
7
Flucytosine Approved, Investigational Phase 2, Phase 3,Phase 1 2022-85-7 3366
8
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
9
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
10
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
11
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
12
Bevacizumab Approved, Investigational Phase 2, Phase 3, Phase 1 216974-75-3
13
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
16
Benzocaine Approved, Investigational Phase 3,Phase 2 1994-09-7, 94-09-7 2337
17
Valproic Acid Approved, Investigational Phase 3,Phase 1,Phase 2 99-66-1 3121
18
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
19
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
20
Cyproheptadine Approved Phase 3 129-03-3 2913
21
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
22
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
23
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5282379 5538
24 tannic acid Approved, Nutraceutical Phase 3,Phase 2
25
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
26
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538
27 Mitolactol Investigational Phase 3 10318-26-0
28 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
29 Dianhydrogalactitol Investigational Phase 3 23261-20-3
30 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
31 Dermatologic Agents Phase 3,Phase 1,Phase 2
32 Dihematoporphyrin Ether Phase 3,Phase 2,Phase 1
33 Ether Phase 3,Phase 2,Phase 1
34 Photosensitizing Agents Phase 3,Phase 2,Phase 1
35 Angiogenesis Inhibitors Phase 2, Phase 3, Phase 1
36 Angiogenesis Modulating Agents Phase 2, Phase 3, Phase 1
37 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
38 Antimitotic Agents Phase 3,Phase 1,Phase 2
39 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
40 Anti-Infective Agents Phase 3,Phase 2,Phase 1
41 Antifungal Agents Phase 2, Phase 3,Phase 1
42 Antimetabolites Phase 2, Phase 3,Phase 1
43 Antirheumatic Agents Phase 3,Phase 2,Phase 1
44 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
45 Keratolytic Agents Phase 3,Phase 1,Phase 2
46 Semustine Phase 3
47
Cobalt Phase 3 7440-48-4 104729
48 Antibodies Phase 2, Phase 3,Phase 1
49 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
50 Endothelial Growth Factors Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 371)

# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
3 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
4 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
5 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
6 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
7 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
8 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
9 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
10 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
11 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
14 Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
15 The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Recruiting NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
16 A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas Recruiting NCT02629757 Phase 3 β-elemene
17 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
18 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
19 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Active, not recruiting NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
20 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3 temozolomide
21 VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Active, not recruiting NCT03149575 Phase 3 VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
22 International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) Not yet recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid;Temozolomide + Chloroquine
23 Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma Terminated NCT00761280 Phase 3 trabedersen;temozolomide;carmustine;lomustine
24 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
25 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
26 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
27 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
28 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
29 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
30 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
31 Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma Unknown status NCT00003176 Phase 2 carmustine;temozolomide
32 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
33 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
34 Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma Completed NCT00003470 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
35 Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma Completed NCT00003537 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
36 Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma Completed NCT00301418 Phase 1, Phase 2 Erlotinib
37 A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Completed NCT00606008 Phase 2 Sunitinib Malate
38 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma Completed NCT00003621 Phase 2 carmustine;cisplatin;etoposide
39 Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse Completed NCT00003775 Phase 2 leflunomide
40 SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) Completed NCT00783393 Phase 2 Temozolomide
41 BNCT to Treat Glioma That Has Progressed Following Radiotherapy Completed NCT00115440 Phase 1, Phase 2
42 Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma Completed NCT00004017 Phase 2
43 Combination Chemotherapy for Patients With Brain Cancer Completed NCT00002814 Phase 2 paclitaxel;topotecan hydrochloride
44 Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma Completed NCT00409214 Phase 2 LS11 (talaporfin sodium)
45 A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas Completed NCT00921167 Phase 2 Bevacizumab/Irinotecan
46 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2 Etirinotecan pegol
47 Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02) Completed NCT00589875 Phase 2 Valacyclovir
48 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
49 Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma Completed NCT00431561 Phase 2 AP 12009 10 µM;AP 12009 80 µM;temozolomide or PCV
50 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)

Search NIH Clinical Center for Grade Iii Astrocytoma

Genetic Tests for Grade Iii Astrocytoma

Anatomical Context for Grade Iii Astrocytoma

MalaCards organs/tissues related to Grade Iii Astrocytoma:

38
Brain, Spinal Cord, Bone, Bone Marrow, T Cells, Liver, Endothelial

Publications for Grade Iii Astrocytoma

Articles related to Grade Iii Astrocytoma:

# Title Authors Year
1
Prolonged survival associated with the use of intraoperative carmustine (Gliadel) in a paediatric patient with recurrent Grade III astrocytoma. ( 23391098 )
2013
2
Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma. ( 20090216 )
2010
3
Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate. ( 16988542 )
2006
4
Mdr1 mRNA expression differs between grade III astrocytomas and glioblastomas. ( 9020393 )
1997
5
Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report). ( 8899347 )
1996
6
p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. ( 1349850 )
1992

Variations for Grade Iii Astrocytoma

Expression for Grade Iii Astrocytoma

Search GEO for disease gene expression data for Grade Iii Astrocytoma.

Pathways for Grade Iii Astrocytoma

Pathways related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 CDK4 CDKN2A CDKN2B EGFR MDM2 PDGFRA
2
Show member pathways
13.71 CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
3
Show member pathways
13.13 CDK4 CDKN2A CDKN2B MDM2 TP53 VEGFA
4
Show member pathways
12.98 CDK4 EGFR MDM2 PDGFRA PTEN TP53
5
Show member pathways
12.95 CDKN2A MDM2 PCNA PTEN TP53
6
Show member pathways
12.9 CDK4 CDKN2A CDKN2B EGFR MDM2 PCNA
7
Show member pathways
12.79 CDK4 CDKN2A CDKN2B EGFR PTEN TP53
8
Show member pathways
12.74 EGFR MDM2 PDGFRA PTEN TP53
9
Show member pathways
12.69 CDK4 MDM2 MGMT PCNA TP53
10
Show member pathways
12.6 CDK4 CDKN2A EGFR MDM2 MMP2 TP53
11
Show member pathways
12.59 CDK4 PCNA PTEN TP53 VEGFA
12
Show member pathways
12.59 CDK4 CDKN2A CDKN2B MDM2 PCNA TP53
13 12.58 CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
14
Show member pathways
12.57 EGFR MMP2 PDGFRA TP53
15
Show member pathways
12.57 CDKN2A MDM2 PCNA TP53
16 12.54 CDK4 CDKN2A MDM2 MGMT PCNA TP53
17 12.5 CDKN2A EGFR MDM2 PDGFRA PTEN TP53
18
Show member pathways
12.49 EGFR PDGFRA PTEN TP53
19
Show member pathways
12.47 EGFR MDM2 TP53 VEGFA
20 12.45 CDK4 CDKN2A CDKN2B PCNA PDGFRA TP53
21
Show member pathways
12.44 EGFR MDM2 PDGFRA TP53
22
Show member pathways
12.4 MDM2 PCNA PTEN TP53
23
Show member pathways
12.4 CDK4 CDKN2A MDM2 PTEN TP53
24 12.38 CDK4 CDKN2A CDKN2B MDM2 PCNA TP53
25
Show member pathways
12.36 CDK4 CDKN2A CDKN2B TP53
26 12.34 EGFR MDM2 MMP2 TP53 VEGFA
27 12.33 CDK4 CDKN2A CDKN2B MDM2 TP53
28
Show member pathways
12.27 CDK4 MDM2 PTEN TP53
29
Show member pathways
12.24 CDK4 EGFR MDM2 PDGFRA PTEN TP53
30 12.21 EGFR MMP2 TP53 VEGFA
31 12.21 CDK4 CDKN2A CDKN2B MDM2 PTEN TP53
32 12.17 CDK4 EGFR MDM2 PTEN TP53 VEGFA
33
Show member pathways
12.16 CDK4 CDKN2A EGFR MDM2 TP53 VEGFA
34
Show member pathways
12.14 EGFR MDM2 MMP2 PTEN
35
Show member pathways
12.12 CDKN2B EGFR MDM2 PTEN
36 12.09 CDKN2A MDM2 MMP2 TP53 VEGFA
37 12.05 CDK4 EGFR GFAP TP53
38 12.05 EGFR MDM2 MMP2 PCNA PTEN TP53
39 12.02 CDKN2A MDM2 PTEN TP53
40 11.98 CDKN2A MDM2 PCNA PTEN TP53
41 11.96 MMP2 TP53 VEGFA
42
Show member pathways
11.94 EGFR GFAP MDM2
43 11.92 CDK4 CDKN2B PTEN TP53
44 11.92 CDK4 CDKN2A MDM2 MGMT PCNA PTEN
45 11.9 CDK4 MMP2 VEGFA
46 11.89 CDK4 MDM2 PCNA TP53
47 11.86 EGFR MDM2 PTEN
48 11.79 GFAP PDGFRA VEGFA
49 11.75 CDKN2A MDM2 TP53
50
Show member pathways
11.75 CDKN2A MDM2 TP53

GO Terms for Grade Iii Astrocytoma

Cellular components related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.4 CDK4 CDKN2A CDKN2B DMBT1 EGFR GFAP
2 protein complex GO:0043234 9.35 CDK4 EGFR MDM2 PDGFRA TP53

Biological processes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.94 CDK4 CDKN2A PTEN TP53
2 positive regulation of gene expression GO:0010628 9.91 CDKN2A MDM2 PTEN TP53 VEGFA
3 response to ethanol GO:0045471 9.81 MGMT PTEN TP53
4 response to toxic substance GO:0009636 9.78 CDK4 MDM2 MGMT
5 response to estradiol GO:0032355 9.77 EGFR PCNA PTEN
6 wound healing GO:0042060 9.75 EGFR PDGFRA TP53
7 protein sumoylation GO:0016925 9.73 CDKN2A MDM2 PCNA
8 epithelial cell differentiation GO:0030855 9.72 DMBT1 PCNA VEGFA
9 response to drug GO:0042493 9.72 CDK4 MDM2 MGMT PTEN TP53
10 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.71 MDM2 PCNA TP53
11 positive regulation of fibroblast proliferation GO:0048146 9.7 CDK4 EGFR PDGFRA
12 positive regulation of DNA replication GO:0045740 9.67 EGFR PCNA PDGFRA
13 response to organic cyclic compound GO:0014070 9.67 EGFR MGMT PTEN TP53
14 response to hyperoxia GO:0055093 9.65 CDK4 TP53
15 positive regulation of protein export from nucleus GO:0046827 9.65 MDM2 TP53
16 positive regulation of cell cycle GO:0045787 9.65 CDK4 MDM2 TP53
17 response to inorganic substance GO:0010035 9.62 PTEN TP53
18 positive regulation of leukocyte migration GO:0002687 9.62 TP53 VEGFA
19 response to lipid GO:0033993 9.61 EGFR PCNA
20 replicative senescence GO:0090399 9.59 CDKN2A TP53
21 DNA ligation GO:0006266 9.58 MGMT PCNA
22 cellular response to reactive oxygen species GO:0034614 9.58 EGFR PDGFRA TP53
23 amyloid fibril formation GO:1990000 9.57 CDKN2A MDM2
24 cellular response to actinomycin D GO:0072717 9.46 MDM2 TP53
25 cellular response to hypoxia GO:0071456 9.46 MDM2 PTEN TP53 VEGFA
26 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.43 PDGFRA VEGFA
27 positive regulation of DNA repair GO:0045739 9.43 EGFR MGMT PCNA
28 negative regulation of apoptotic process GO:0043066 9.43 EGFR MDM2 MGMT PTEN TP53 VEGFA
29 positive regulation of cell proliferation GO:0008284 9.1 CDK4 EGFR MDM2 PDGFRA PTEN VEGFA
30 multicellular organism development GO:0007275 10.1 CDK4 DMBT1 EGFR PDGFRA TP53 VEGFA
31 phosphorylation GO:0016310 10.04 CDK4 CDKN2A CDKN2B EGFR PDGFRA

Molecular functions related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.8 CDK4 CDKN2A CDKN2B EGFR PDGFRA
2 protein kinase binding GO:0019901 9.72 CDKN2A CDKN2B EGFR PTEN TP53
3 identical protein binding GO:0042802 9.7 EGFR GFAP MDM2 PCNA PTEN TP53
4 enzyme binding GO:0019899 9.65 EGFR MDM2 PCNA PTEN TP53
5 SUMO transferase activity GO:0019789 9.43 CDKN2A MDM2
6 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.37 CDKN2A CDKN2B
7 disordered domain specific binding GO:0097718 9.13 CDKN2A MDM2 TP53
8 platelet-derived growth factor receptor binding GO:0005161 8.8 PDGFRA PTEN VEGFA

Sources for Grade Iii Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....